SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces the publication of ...

SkylineDx has published a new study marking a “significant advancement” in understanding and identifying high-risk multiple ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells. Your plasma cells are a type of white blood cell inside your bone marrow, the ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

German Multicenter Myeloma Group; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; HRCA, high-risk cytogenetic abnormality; ISS, International Staging System as assessed at trial entry; MM, ...

Your healthcare team will use the Revised International Staging System (RISS) to determine if you have stage 1, stage 2, or stage 3 multiple myeloma. This staging system is based on blood lab ...

Footnotes: Zhou et al. Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma. Combining SKY92 gene expression profiling and FISH ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.